Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nevertheless, the large gene FHIT that includes FRA3B, the most highly expressed CFS in human lymphocytes, is commonly deleted in a variety of tumors suggesting a tumor suppressor role for its product.
|
31646677 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Heterozygous loss of the tumor-suppressor fragile histidine triad (FHIT) gene also was observed, although protein expression was preserved.
|
30248342 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Despite this, there are some controversies about the exact role of the FHIT gene in relation to tumor biology.
|
29516675 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
New interactions between tumor suppressor Fhit protein and a nonhydrolyzable analog of its A<sub>P</sub><sub>4</sub> A substrate.
|
28094435 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT is a genome caretaker/tumor suppressor that is silenced in >50% of cancers.
|
29282095 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
According to the results of clinical information, there were significant associations of FHIT expression with TNM-stage (RR =2.13, 95% CI =1.72-2.64), tumor size (RR =1.67, 95% CI =1.36-2.05), and merger of cirrhosis (RR =1.34, 95% CI =1.06-1.69) of liver cancer in the Chinese population.
|
28790842 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair.
|
29069730 |
2017 |
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
In addition, FHIT promoter methylation was correlated with clinical stage (advanced stage vs early stage: odds ratio = 2.69, p = 0.056) and tumor grade (high grade vs low grade: odds ratio = 4.11, p < 0.001).
|
28639889 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of miR-143, miR-663a and miR-668 were significantly reduced in FHIT downregulated tumors. miR-668 expression was also significantly altered relative to FHIT down- and up- regulated tumor tissues.
|
27236032 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging evidence indicates that FHIT is a candidate tumor suppressor in many types of tumors including non-small-cell lung carcinoma (NSCLC).
|
26929601 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT is a tumor suppressor gene that is frequently silenced in non-small cell lung cancer (NSCLC) and also in preneoplastic lesions.
|
27572663 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Emerging evidence indicates that FHIT is a candidate tumor suppressor in non-small cell lung cancer (NSCLC).
|
26796853 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT is a bona fide tumor-suppressor gene and its loss contributes to tumorigenesis of epithelial cancers including breast cancer (BC).
|
26491255 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fragile histidine triad (FHIT) gene is a tumor suppressor gene which involved in breast cancer pathogenesis.
|
25735361 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, we suggest that restoration of the miR-29b expression using the c-Myc inhibitor might be helpful in suppressing tumor aggressiveness mediated by FHIT loss and consequently improving outcomes in NSCLC patients with tumors with low expression of FHIT.
|
24909176 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor samples in this cohort with normal FHIT expression do not exhibit APOBEC hypermutation, despite having high APOBEC3B expression.
|
25401976 |
2015 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of FHIT mRNA was significantly decreased in FHIT LOH positive tumors (p = 0.027).
|
24370550 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A number of studies have indicated that the Fragile Histidine Triad (FHIT) gene product, FHIT, functions as a tumor suppressor in a variety of common human cancers.
|
25340791 |
2014 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Indeed, recent reports have reconfirmed FHIT as a tumor suppressor gene with roles in apoptosis and prevention of the epithelial-mesenchymal transition.
|
25283145 |
2014 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The fragile histidine triad (FHIT) gene is a putative tumor suppressor gene in breast and other types of cancer, and loss of Fhit expression has been observed in breast cancer.
|
23969757 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Fhit protein is lost or reduced in a large fraction of human tumors, and its restoration triggers apoptosis and suppresses tumor formation or progression in preclinical models.
|
24223161 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we show by molecular combing that a small but significant percentage of normal human cells carry an abnormal sequence pattern within the tumor suppressor gene FHIT (3p14.2) at FRA3B.
|
23780737 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Simultaneously, the allelic deletion status of fragile histidine triad (FHIT) gene was studied by FISH in cRCC and major epithelial carcinoma (MEC) tumors.
|
21962529 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
FHIT and p53 are the two most commonly altered tumor suppressor genes in lung cancer, and their molecular status regulates sensitivity to anticancer drugs.
|
22425911 |
2012 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
FRA3B and FRA16D are the most sensitive common chromosomal fragile site loci in the human genome and two tumor suppressor genes FHIT (Fragile Histidine Triad) and WWOX (WW domain-containing oxidoreductase gene) map to this sites.
|
21983861 |
2012 |